Coenzyme Q₁₀ and its Relation with Oxidant and Antioxidant System Markers in Patients with End-Stage Renal Disease

Figures & data

Table 1. Demographic and laboratory characteristics of hemodialysis, peritoneal dialysis, and chronic kidney disease patients.

Parameter	Hemodialysis	Peritoneal dialysis	CKD
Patient number	40	60	40
Age (years)	54.8 ± 15.1	53.2 ± 14.1	57.8 ± 14.5
Dialysis vintage (months)	70.3 ± 44.2^a	46.7 ± 23.8
Hemoglobin (g/L)	11.0 ± 1.3^b	11.5 ± 1.7^c	12.5 ± 1.8
Hematocrit (%)	35.9 ± 4.3	34.8 ± 5.3^c	37.9 ± 5.2
BUN (mg/dL)	132.9 ± 23.5^a,^b	101.5 ± 29.3^c	81.4 ± 34.6
Creatinine (mg/dL)	8.8 ± 2^b	7.9 ± 2.8^c	2.5 ± 0.9
Calcium (mg/dL)	8.8 ± 1.1^b	9.1 ± 0.9	9.4 ± 0.4
Phosphorus (mg/dL)	4.8 ± 1.1^a,^b	3.8 ± 0.9	3.5 ± 0.6
iPTH (pg/mL)	237.1 ± 167.5^a,^b	513.6 ± 465.3^c	154.6 ± 86.6
Total protein (mg/dL)	7.4 ± 0.5^a	6.8 ± 0.7^c	7.2 ± 0.6
Albumin (mg/dL)	3.9 ± 0.3^a	3.8 ± 0.4^c	4.1 ± 0.4
CRP (mg/dL)	13.9 ± 21.3^b	19.7 ± 13.0^c	30.2 ± 14.9
Total cholesterol (mg/dL)	179.7 ± 38.4^a	200.1 ± 53.2^c	172.2 ± 40.3
Triglycerides (mg/dL)	184.6 ± 137.1	158.2 ± 75.2	153.8 ± 91.6
HDL (mg/dL)	37.2 ± 11.7	41.3 ± 14.1	36.8 ± 10.6
LDL (mg/dL)	109.6 ± 36.6^a	127.5 ± 44.6^c	104.0 ± 32.2

Notes: ^aSignificant difference (p < 0.05) between HD and PD.

^bSignificant difference (p < 0.05) between HD and CKD.

^cSignificant difference (p < 0.05) between PD and CKD.

Table 2. Serum levels of malondialdehyde, uric acid, CoQ₁₀, superoxide dismutase, and antioxidant capacity in CKD, hemodialysis, and peritoneal dialysis patients.

	CKD	Hemodialysis	Peritoneal dialysis
Malondialdehyde (μmol/L)	10.80 ± 3.34	9.97 ± 3.39	11.58 ± 3.95
Uric acid (mg/dL)	8.26 ± 2.80	6.37 ± 1.76^a	5.86 ± 1.25^a
Superoxide dismutase (U/mL)	0.86 ± 0.19	0.99 ± 0.42	1.03 ± 0.22^a
Antioxidant activity (mmol/L)	1.13 ± 0.24	0.75 ± 0.24^a	1.24 ± 0.25^a,^b
Coenzyme Q10 (mg/L)	0.47 ± 0.15	0.49 ± 0.12	0.46 ± 0.17

Notes: ^aCompared with CKD (p < 0.05).

^bCompared with hemodialysis (p < 0.05).